Assignment: prescribed oprelvekin therapy

Assignment: prescribed oprelvekin therapy

Permalink:

Question 17 A female patient is prescribed oprelvekin therapy to treat thrombocytopenia. Which of the following should the nurse continuously monitor to determine the efficacy and duration of the oprelvekin therapy?

A) Weight gain

B) Platelet count

C) Red and white blood cell count

D) Cardiac arrhythmias

Question 18 During ongoing assessment of a patient receiving 5-FU therapy, the nurse finds the patient’s platelet count to be 92,000 cells/mm3. The nurse should do which of the following?

A) Consult the prescriber for an increase in dosage

B) Consult the prescriber for a decrease in dosage

C) Consult the prescriber for discontinuation of the drug

D) Continue the therapy as prescribed

Question 19 A nurse has been assigned to a female patient who is to begin chemotherapy. The nurse will initiate the prescribed oprelvekin therapy

A) 6 to 24 hours after chemotherapy.

B) 2 days after chemotherapy.

C) 6 days after chemotherapy.

D) 10 days after chemotherapy.

Question 20 A patient with a recent diagnosis of chronic myelogenous leukemia (CML) is discussing treatment options with his care team.What aspect of the patient’s condition would contraindicate the use of cyclophosphamide for the treatment of leukemia?

A) The patient has a diagnosis of type 2 diabetes and takes oral antihyperglycemics.

B) The patient has had a history of nonadherence to medical treatment.

C) The patient’s bone marrow function is significantly depressed.

D) The patient has decreased renal function.

Question 21 A female patient has follicular non-Hodgkin’s lymphoma and is receiving thalidomide (Thalomid). It will be most important for the nurse to monitor this patient for which of the following?

A) Angina

B) Fever

C) Chills and rigors

D) Bleeding

Question 22 When planning care for a patient who is receiving filgrastim (Neupogen) for a nonmyeloid malignancy, the nurse should formulate which of the following patient outcomes? (Select all that apply.)

A) The patient will not develop an infection.

B) The patient will not experience bone pain.

C) The patient will be able to self-administer filgrastim at home.

D) The patient will not develop febrile neutropenia.

E) The patient will not retain fluid.